Slower metabolism: Your body might burn fewer calories post-treatment, making weight gain easier
The FDA label sets the boundary at "more than 2 days" between consecutive doses
Announced by Novo Nordisk on January 17, 2025, the randomized, double-blinded, parallel-group, placebo-controlled STEP UP trial evaluated the efficacy of semaglutide 7.2 mg to semaglutide 2.4 mg (Wegovy) and placebo in more than 1400 adults with obesity and without type 2 diabetes (T2D)
It belongs to a group of medications called GLP-1 receptor agonists, which help regulate appetite and blood sugar levels
It requires patience and commitment
However, the mechanical process of measuring units is identical